PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle mass alongside GLP-1 therapies. This emerging category is gaining industry attention due to its potential to enhance body composition and patient results, supported by strategic acquisitions like Eli Lilly's purchase of Versanis Bio. The report suggests muscle-preservation therapies will complement rather than replace GLP-1 drugs, creating new opportunities in pharmaceutical partnerships, licensing, and intellectual property. This marks a shift in obesity treatment focus from just weight loss to improving the quality of weight loss over time.
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by ...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
Weight Watchers has partnered with Eli Lilly's digital platform LillyDirect to offer its Med+ program, combining GLP-1 medication access with clinical and behavioral support. This integration aims to provide patients nationwide with a comprehensive w...
Chai Discovery, an AI drug discovery startup, has secured major partnerships with pharmaceutical giants Pfizer and Eli Lilly to develop new antibody-based therapies using its advanced AI models. Valued at $1.3 billion, Chai recently launched its impr...
Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, de...
